| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
S83410-1mg促销 |
≥98% | ￥550.00 ￥430.00 |
10 | - | - | - | - |
|
S83410-5mg促销 |
≥98% | ￥990.00 ￥790.00 |
10 | - | - | - | - |
|
S83410-10mg促销 |
≥98% | ￥1650.00 ￥1310.00 |
10 | - | - | - | - |
|
S83410-25mg促销 |
≥98% | ￥3300.00 ￥2630.00 |
6 | - | - | - | - |
|
S83410-50mg促销 |
≥98% | ￥4800.00 ￥3830.00 |
3 | - | - | - | - |
|
| 产品描述： | Cetrorelix Acetate is gonadotropin-releasing hormone (GnRH) receptor antagonist with an IC50 of 1.21 nM. | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点： | GNRH Receptor;GNRHReceptor | ||||||||||||||||||||
| 体内研究： | Cetrorelix inhibits the activation of hGnRHR and a downstream luciferase reporter gene in murine LTK- cells by the GnRHR agonist [D-Trp6]GnRH (IC50 = 1.2 nM). In vivo, cetrorelix (60 μg per day) reduces tumor volume to 35% of control and decreases serum luteinizing hormone levels by 50% in a human epithelial ovarian cancer mouse xenograft model | ||||||||||||||||||||
| 参考文献： | 1. Yano T , Pinski J , Halmos G , et al. Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75.[J]. Proceedings of the National Academy of Sciences, 1994, 91(15):7090-7094. 2. Gründker, Carsten, Emons, Günter. Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer[J]. Reproductive Biology & Endocrinology Rb & E, 2003, 1(1):65-65. | ||||||||||||||||||||
| 溶解性： | Soluble in DMSO | ||||||||||||||||||||
| 保存条件： | -20°C | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京